Circio Holding ASA

Circio Holding ASA Funding requested under additional financing commitment from Atlas

Oslo, Norway 4 August 2025: Reference is made to the financing commitment

provided by Atlas to fund the Company's operations until the end of June 2025.

The financing commitment has been extended to enable funding flexibility to

the end of the fourth quarter 2025 (the "Additional Financing Commitment").

The Company has by a notice of exercise requested Atlas to subscribe and pay

for one additional tranche of convertible bonds, consisting of 11 convertible

bonds with an aggregate principal amount equal to NOK 5,500,000. Atlas will be

allocated these bonds under the terms and conditions of the Investment

Agreement.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683 34 3811

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic cassette design for

efficient biogenesis of multifunctional circRNA inside cells. The circVec

platform has applications in multiple therapeutic settings, including genetic

medicine, cell therapy and chronic disease. It has demonstrated over 70-fold

prolonged RNA half-life and up to 15-fold enhanced protein expression vs.

conventional mRNA vector systems in vivo, and has the potential to become a

new gold-standard protein expression technology. The circRNA R&D activities

are being conducted by the wholly owned subsidiary Circio AB in Stockholm,

Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

AI Terminal